Streetbeat News

Stock Prices

DUOL

FIGS

VCSA

VLCN

In Thursday's pre-market session, 12 consumer discretionary stocks showed significant movement. Volcon, J-Long Group, and Bright Scholar Education were among the top gainers, with Volcon leading at a 79.3% increase. Duolingo also saw a notable rise after its Q4 earnings release. On the downside, Vacasa, WW International, and FIGS experienced significant drops, with their recent Q4 earnings impacting their stock prices.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:07 pm

BFLY

ENVB

IRWD

In Thursday's pre-market session, several healthcare stocks showed significant movement. Enveric Biosciences, Societal CDMO, and NeuroBo Pharmaceuticals were among the top gainers, with Enveric Biosciences leading at a 162.3% increase. On the losing side, Ironwood Pharmaceuticals, Milestone Pharmaceuticals, and Butterfly Network saw notable declines, with Ironwood Pharmaceuticals dropping by 27.7%. Earnings releases influenced some of the stock movements.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:07 pm

AGFY

AMRC

SHLS

STEM

XMTR

In Thursday's pre-market session, several industrials stocks showed significant movement. Agrify, Sterling Check, Nxu, Sidus Space, and Royalty Management Holdings were among the top gainers, with Agrify leading at a 28.5% increase. On the downside, Xometry, Shoals Technologies Group, Stem, First Advantage, Energy Focus, and Forward Air experienced declines, with Xometry dropping the most at 17.6%. Notably, earnings reports influenced several of these movements, including Ameresco, Xometry, Shoals Technologies Group, Stem, First Advantage, and Forward Air.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:06 pm

SLS

SELLAS Life Sciences announced it will present Phase 1 data for SLS009 from Acute Myeloid Leukemia patients at the 2024 ESH Conference. This marks a significant milestone in the development of SLS009 and its potential impact on treating Acute Myeloid Leukemia.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:06 pm

DAVA

OKTA

SNOW

In Thursday's pre-market session, several information technology stocks showed significant movement. Okta, Spectaire Holdings, C3.ai, SMX, Ondas Holdings, and Vertex were among the gainers, with Okta leading with a 23.4% increase following its Q4 earnings report. On the losing side, Endava, Snowflake, DoubleVerify Holdings, LivePerson, Presto Automation, and Focus Universal saw declines, with Endava dropping 21.7% after its Q2 earnings report.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:06 pm

MSC

Studio City Intl Hldgs (NYSE:MSC) reported a significant improvement in its Q4 earnings, with losses narrowing to $(0.10) per share from $(0.43) YoY, and sales skyrocketing to $141.25M from $4.24M YoY.

Portfolio Pulse from totan@benzinga.com

February 29, 2024 | 1:06 pm

PCRX

Pacira BioSciences (NASDAQ:PCRX) reported Q4 adjusted EPS of $0.89, beating the $0.88 estimate, but missed sales estimates with $181.24M versus the expected $181.66M. This represents a 21.92% increase in EPS and a 5.40% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:04 pm

DUOL

OKTA

SCTL

SNOW

VLCN

Okta, Inc. (NASDAQ:OKTA) shares surged in pre-market trading by around 24% after reporting Q4 earnings and sales that exceeded analyst expectations, alongside strong guidance. Other stocks also showed significant pre-market movements, with notable gainers including Volcon, Inc. (NASDAQ:VLCN), Societal CDMO, Inc. (NASDAQ:SCTL), and Duolingo, Inc. (NASDAQ:DUOL) due to various positive developments. Conversely, Snowflake Inc. (NYSE:SNOW) and WW International, Inc. (NASDAQ:WW) were among the prominent losers, with Snowflake's CEO retiring and WW International reporting disappointing Q4 results.

Portfolio Pulse from Avi Kapoor

February 29, 2024 | 1:04 pm

ACLX

Arcellx, Inc. (NASDAQ:ACLX) reported a significant turnaround in its Q4 results with a net income of $20.5 million, compared to a net loss of $39.0 million in the previous year. The company's collaboration revenue soared to $63.1 million, up from zero. Research and development expenses increased slightly. The company highlighted its expanded partnership with Kite, a $200M investment extending its cash runway into 2027, and presented promising data for anito-cel as a treatment for multiple myeloma. Following the report, Baird and Needham raised their price targets for ACLX, though its shares fell slightly by 0.4% to close at $67.32.

Portfolio Pulse from Avi Kapoor

February 29, 2024 | 1:03 pm

TRS

TriMas (NASDAQ:TRS) reported Q4 2023 earnings of $0.37 per share, missing the $0.53 estimate, and sales of $209.56M, missing the $246.44M estimate. This represents a 40.32% decrease in earnings and a 3.07% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:02 pm